(Q42869555)

9 November 2017

title

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study (English)

1 reference

9 November 2017

1 reference

1 reference

Brooke Harrison

1

1 reference

9 November 2017

Mindy H Magee

2

1 reference

9 November 2017

Arun Mandagere

3

1 reference

9 November 2017

Gennyne Walker

4

1 reference

9 November 2017

Christopher Dufton

5

1 reference

9 November 2017

Linda S Henderson

6

1 reference

9 November 2017

Ramesh Boinpally

7

1 reference

9 November 2017

publication date

1 January 2010

1 reference

Clinical Drug Investigation

9 November 2017

published in

1 reference

9 November 2017

volume

30

1 reference

9 November 2017

issue

12

1 reference

9 November 2017

page(s)

875-885

1 reference

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

9 November 2017

cites work

1 reference

12 December 2020

Dual effects of rifampin on the pharmacokinetics of atrasentan.

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

1 reference

12 December 2020

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil

1 reference

12 December 2020

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

1 reference

12 December 2020

Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite

1 reference

12 December 2020

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

1 reference

12 December 2020

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

12 December 2020

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

1 reference

12 December 2020

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

12 December 2020

Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism

1 reference

12 December 2020

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

1 reference

12 December 2020

Pharmacokinetics of oral and intravenous rifampicin during chronic administration

1 reference

12 December 2020

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

1 reference

12 December 2020

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

12 December 2020

10.2165/11539110-000000000-00000

Identifiers

DOI

1 reference

9 November 2017

1 reference